alexa Recent Advances in Molecular Targeted Therapy for advan
ISSN: 2161-0398

Journal of Physical Chemistry & Biophysics
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

Recent Advances in Molecular Targeted Therapy for advanced Colorectal Cancer and Non–Small Cell Lung Cancer

Toshihiro Tanaka* and Kazuo Tamura
Division of Oncology, Hematology, and Infectious Diseases, Department of Internal Medicine, Fukuoka University, Japan
Corresponding Author : Toshihiro Tanaka
Department of Internal Medicine
Fukuoka University, Fukuoka, Japan
Tel: +81-92-801-101
Fax: +81-92-865-5656
E-mail: [email protected]
Received July 10, 2012; Accepted October 27, 2012; Published October 29, 2012
Citation: Tanaka T, Tamura K (2012) Recent Advances in Molecular Targeted Therapy for advanced Colorectal Cancer and Non–Small Cell Lung Cancer. J Phys Chem Biophys 2:108 doi:10.4172/2161-0398.1000108
Copyright: © 2012 Tanaka T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
 

Abstract

Cancer remains one of the most life-threatening diseases to date. Traditionally, chemotherapy treatments for locally advanced or metastatic cancer had little or no efficacy. For example, colon and lung cancers were associated with poor clinical outcomes as recently as a decade ago. However, increased understanding of the molecular mechanisms underlying carcinogenesis has spurred focus on the development and incorporation of molecular targeted agents in current therapeutic options for these difficult-to-treat diseases. Such agents have the ability to target a variety of cancer relevant molecules, including epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) and its receptor. In addition, protein tyrosine kinases have been proven to be good targets to develop small molecule inhibitors that compete with ATP and inhibit kinase activity. These inhibitors have clinically effective responses. In this review, we describe the current status of targeted therapies in the treatment of advanced colon and lung cancers
focusing on clinical data based on experience with in monoclonal antibodies and tyrosine kinase inhibitors acting in these pathways.

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords